



Marksans Pharma Ltd.

Date: 19th April, 2023

BSE Limited

Corporate Relation Department
PhirozeJeejeeboi Towers,
Dalal Street,
Mumbai - 400001.
Scrip Code: 524404

National Stock Exchange of India Limited

Listing Department
Exchange Plaza, C-1, Block-G,
Bandra-Kurla Complex,
Bandra (East), Mumbai - 400051.
Symbol: MARKSANS

Sub: Press Release / News Release

Dear Sir,

Enclosed herewith kindly find the press release dated 19th April, 2023 of the Company

You are requested to note the above in your records.

Thanking You.

Yours faithfully,

For Marksans Pharma Limited

Harshavardhan Panigrahi
Company Secretary



Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara,
Andheri (W), Mumbai - 400 053 Tel.: +91 22 4001 2000 E-mail: info@marksanspharma.com
www.marksanspharma.com



Marksans Pharma Ltd.

Marksans Pharma completes the acquisition from Tevapharm India, expanding the existing manufacturing capacity in India

Mumbai, April 19, 2023– Marksans Pharma Ltd. (NSE: MARKSANS; BSE:524404), one of the fastest-growing pharmaceutical companies in India, has completed the acquisition of a manufacturing site from Tevapharm India in Plot No. AI, Phase I-A, Verna Industrial Estate, Verna, Goa 403722, India. The acquisition was first announced in October 2022.

With the completion of the acquisition, Marksans will start operating at the acquired facility. As a part of the agreement, Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards. The contract manufacturing agreement with Teva is to continue providing an uninterrupted supply of Teva's important medicines to customers and patients. Marksans has retained the transferring employees on terms materially similar to its current employment. Teva's adjoining Watson Pharma Private Limited's site is not part of the divestment with Marksans and will remain with Teva.

The acquired facility will enable Marksans Pharma to potentially double the existing Indian capacity from 8bn units per annum currently. It is a scalable capacity to manufacture oral solid dosage forms. Marksans plans to manufacture tablets, hard and soft gel capsules, ointments, liquids, and creams, from the new capacity. The manufacturing site is spread across 47,597 square meters and has approvals to manufacture products from the EU, Health Canada & Japanese Health Authority.

Commenting on the acquisition, Mark Saldanha, Managing Director of the Company said *"The completion of the manufacturing capacity from Tevapharm India is a significant milestone to strengthen our position as a leading low-cost manufacturer and to provide high-quality products to meet the growing demands of our customers. It will accelerate the growth of our business while expanding our product base and market share gains. We remain committed to investing in our future, and this will set the stage for the next phase of our growth journey."*

Annexure A:

Current Capacity (per annum)	Location
8 bn	Goa
4 bn	UK
6 bn	USA
18 bn	Overall capacity across 3 locations
New Capacity (Potential per annum)	Location
8 bn	The acquired facility from Tevapharm – Goa
26 bn	Overall Potential Capacity including the new acquired facility



About Teva:

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people's lives for more than a century. They are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with their established presence in generics, they have significant innovative research and operations supporting their growing portfolio of specialty and biopharmaceutical products.

About Marksans Pharma:

Marksans Pharma Ltd. (www.marksanspharma.com) headquartered in Mumbai, India is engaged in the Research, Manufacturing & Marketing of generic pharmaceutical formulations in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies including USFDA, UKMHRA, and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Antidiabetic, Pain Management, Gastroenterological, cough & cold and Anti-allergies. The company is marketing these products globally.

Disclaimer

Certain statements in this press release concerning our future growth prospects may be forward-looking statements, which involve several risks, and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The company's results may be affected by factors including, but not limited to, the risks and uncertainties in pharmaceutical research and development; competitive developments; regulatory actions; the extent and duration of the effects of the COVID-19 pandemic; litigation and investigations; business development transactions; economic conditions; and changes in laws and regulations, including health care reform. The company undertakes no duty to update forward-looking statements except as required by applicable law.

Contact Information

Jitendra Sharma, CFO

Marksans Pharma Ltd

Tel: +91 022 40012000

jitendra@marksanspharma.com

Registered Office

11th Floor, "GRANDEUR"

Off Veera Desai Extension Road

Oshiwara, Andheri West

Mumbai, Maharashtra, 400 053

Telephone: +91 224001 2000

Fax: +91 224001 2011

CIN: L24110MH1992PLC066364

ISIN: INE750C01026

NSE Code: MARKSANS

BSE CODE: 524404

Website: <http://www.marksanspharma.com>

